SIK2 attenuates proliferation and survival of breast cancer cells with simultaneous perturbation of MAPK and PI3K/Akt pathways
Metrics: PDF 1589 views | HTML 2364 views | ?
Neslihan Zohrap1, Özge Saatci2, Burcak Ozes1, Ipek Coban3, Hasan Murat Atay4, Esra Battaloglu1, Özgür Şahin2 and Kuyas Bugra1,5
1Department of Molecular Biology and Genetics, Bogazici University, Istanbul, Turkey
2Department of Molecular Biology and Genetics, Bilkent University, Ankara, Turkey
3Department of Pathology, Istanbul Florence-Nightingale Hospital, Istanbul, Turkey
4Department of General Surgery, Gayrettepe Florence-Nightingale Hospital, Istanbul, Turkey
5Life Sciences Center, Bogazici University, Istanbul, Turkey
Kuyas Bugra, email: [email protected]
Keywords: SIK2; tumor suppressor; breast cancer; Ras/ERK and PI3K/Akt signaling; EMT
Received: October 19, 2017 Accepted: March 09, 2018 Published: April 24, 2018
Salt Inducible Kinase2 (SIK2) has been shown to contribute to tumorigenesis in multiple tumor types in a dichotomous manner. However, little is known about its contribution to breast malignancies. Here, we report SIK2 as a potential tumor suppressor in breast cancer whose expression was reduced in tumor tissues and breast cancer cell lines compared to normal counterparts. In vitro loss- and gain-of-function experiments combined with xenograft studies demonstrated that SIK2-mediated attenuation of proliferation and survival of breast cancer cells with parallel inhibition of both Ras/Erk and PI3K/Akt pathways. Our findings elucidated that SIK2 has also an inhibitory role in migration/invasion ability of breast cancer cells through regulation of epithelial mesenchymal transition. Immunostaining of patient tumors revealed that SIK2 protein level is frequently downregulated in invasive mammary carcinomas and negatively correlated with the mitotic activity of the cells in triple negative breast cancers and hormone positive tumors. Strikingly, patient survival analysis indicated that higher levels of SIK2 are significantly associated with better survival, especially in basal breast cancer cases. Overall, our findings suggest SIK2 as a potential tumor suppressor in the control of breast tumorigenesis, at least in part, via inhibiting PI3K/Akt and Ras/ERK signaling cascades simultaneously and a novel prognostic marker, especially in basal subtypes of breast cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.